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Abstract
Salvage therapy in head and neck cancer (HNC) is a controversy issue and the literature is scarce
regarding the use of interstitial high-dose rate brachytherapy (I-HDR) in HNC. We evaluated the
long-term results of a treatment policy combining salvage surgery and I-HDR for cervical
recurrences of HNC. Charts of 21 patients treated from 1994 to 2004 were reviewed. The crude
local control rate for all patients was 52.4%. The 5- and 8-years overall (OS) and local relapse-free
survival (LRFS) rates were 50%, 42.9%, 42.5% and 28.6%, respectively. The only predictive factor
associated to LFRS and OS was negative margin status (p = 0.0007 and p = 0.0002). We conclude
that complete surgery is mandatory for long term control and the doses given by brachytherapy
are not high enough to compensate for microscopic residual disease after surgery.
Background
The best approach for advanced head and neck cancer
(HNC) is the combined modality using surgery, adjuvant
radiotherapy with or without chemotherapy. For patients
who refuse surgery, the superiority of radiation (RT) con-
current with chemotherapy (CHT) in local and regional
tumor control has been established in several randomized
studies and meta-analyses [1,2], but even for multimodal-
ity treated patients the recurrence rates above the clavicles
occur in up to 20% of patients [3,4].
Salvage therapy in HNC is still a controversy issue and the
best combination approach is still to be defined. It seems
that maximum debulking surgery combined to a primary
or a second new course of RT can lead to a better local con-
trol (LC). Conversely, a new course of external beam radi-
otherapy (EBRT) for recurrent disease is always a problem
and of limited feasibility because of the difficulty to spare
adjacent normal tissues, resulting in undesirable late
effects on the salivary glands, mandible, and muscles of
mastication. In these cases the use of intra-operative inter-
stitial implantation is an option, as it is ideally suited to
deliver a high dose to a limited volume, thus minimizing
sequelae and improving LC [5]. I-HDR can also increase
total biological effective dose administered when com-
pared to a second course of EBRT, the overall time is
decreased and it is also a very conformal way of treatment,
allowing protection of normal surrounding structures [6].
In 1996 we started an institutional treatment policy of
post-operative I-HDR for recurrent cervical carcinomas,
with tumor control on the site of the primary, to take
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advantage of shortening the overall treatment time and
conformability of the procedure.
Patients and methods
All patients admitted for treatment at the Radiation
Oncology and Head and Neck Surgery Departments, Hos-
pital do Cancer A.C. Camargo, São Paulo, Brazil, from
October 1994 to June 2004, were retrospectively selected.
The criteria for including patients in the study were: recur-
rent cervical cancer with local control of the primary site,
biopsy proven squamous cell carcinoma (SCC), Karnof-
sky performance 60 and above, possibility of surgical
resection no evidence of distant metastasis. A total of 21
patients were selected and the clinical stage defined based
on preoperative clinical and radiological examinations,
using the TNM classification of the AJCC [7]. Clinical
characteristics of patients at presentation are summarized
in Table 1.
We observed that the initial evaluation for all patients
consisted of a history and physical evaluation, including a
careful locorregional exam, chest X Rays, and routine
serum laboratory studies (complete blood count, bio-
chemistry panel) and detailed information about the first
course of EBRT. After a multidisciplinary team evaluation
and the approval of a Review Board the procedure was
performed.
All patients underwent to complete gross tumor resection.
The details of treatment have been published elsewhere
[8]. In summary, the treatment policy was as follows: all
patients should have a pretreatment evaluation of the
tumor target volume and normal tissue volumes at risk at
Radiation Oncology Department. At the moment of the
surgery, plastic catheters were inserted as parallel as possi-
ble, 10–15 mm apart one of each in the tumor bed with
15 to 20 mm margin. In a first moment, metallic markers
were also inserted to help on defining the target volume at
the planning system. Grafts were used, when indicated, to
cover the tumor bed and to spare vascular structures and
nerves or to overlay the catheters. Most patients had single
plan implants, but whenever necessary biplane implants
were performed.
For I-HDR planning and reconstruction, radiographs or
CT scans were used in order to calculate exactly the dose
distribution to the target volume and adjacent healthy tis-
sues (Figure 1). The micro-Selectron HDR, Nucletron, or
Gammamed-Varian equipment, with iridium-192 sources
were used for treatment delivery (Nucletron B.V., Nether-
lands and Varian, Palo Alto, US). Plans were optimized
using standard geometric optimization, and prescription
dose was based on the Paris dosimetry system. Dose pre-
scriptions were at the isodose that encompassed the
tumor bed with a safety margin of 5 mm (median: 87%,
Three-dimensional planning CT image reconstruction Figure 1
Three-dimensional planning CT image reconstruction.
Table 1: Characteristics of patients with cervical recurrences and 
local control of the tumor primary site
Variables n. pacients % median
Age 53.5
< 65 years 15 71.4
≥ 65 years 62 8 . 6
Gender
Male 16 76.2
Female 52 3 . 8
Primary Tumor Site
Cervical 14 . 8
Face (skin SCC)4 1 9 . 0
Pharynx 10 47.6
Oral cavity 62 8 . 6
Lymph node mobility
Mobile 12 57.1
Reduced 62 8 . 6
Fixed 31 4 . 3
Previous Radiation
Yes 15 71.4
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range: 75–95%). Hot spots should not exceed 135% of
prescribed dose, in one fourth of total irradiated target
volume. Doses at the skin were measured and should not
exceed 60% of the prescribed dose. The doses to spinal
cord were measured and limited by the presence of a pre-
vious EBRT course. No patient had a nominal total dose
above 48 Gy to the spinal cord.
Fifteen of the patients who presented cervical recurrence
had had a previous course of external beam radiation with
doses ranging from 30 to 66 Gy (median 52 Gy). For the
second course of EBRT photons of 4 MV or 6 MV were
used. The EBRT course usually started immediately after
the completion of the course of I-HDR.
Statistical analysis
The actuarial survival rates were calculated by the Kaplan
Meyer method. Chi-square tests were used to find differ-
ences in proportions and the Log-rank test was used to
compare equality of survivor functions. The Cox propor-
tional risk model was used for establishing a multi-facto-
rial model considering the variables with independent
prognostic value and the T-test was used to compare
means. The follow up time was defined as the interval
between the date of being admitted to the hospital and
the date of the last objective follow up information or
death.
Statistical significance was considered for p-values < 0.05.
Results
The median age of patients was 53.5 (range 31–73) years
and the follow up time ranged from 6 to 82 months
(median – 36 months). The median interval between first
treatment and salvage therapy was 32 months (range 14–
86). The characteristics of patients are shown in table 1.
There was a predominance of male patients (76.2%) and
the ratio male to female was 3.2:1. Fifteen patients
(71.4%) had previous EBRT with doses ranging from 30
Gy to 66 Gy (median 52 Gy).
The total dose of I-HDR for all patients ranged from 12 Gy
to 48 Gy (median 35), given in 3 to 16 fractions (median
8 fractions), in a median of 4 days (range 3 to 8). The
median interval between the surgical intervention and
start of I-HDR was 5 days (range 4–12). The median
number of catheters inserted was 4 (range, 4–9) per
patient. Two (9.5%) patients had double planar implants,
and the remaining single plan implants.
The interval between the end of I-HDR and the start of the
second course of EBRT ranged from 1 to 37 days (median
7 days). No patient had concurrent I-HDR and CHT, but
one patient had concurrent platinum based CHT at time
of EBRT course. The total treatment time, including the
surgical procedure, ranged from 14 to 72 days (median 38
days).
All patients had combined EBRT and I-HDR. The median
dose of EBRT was 45 Gy (range 30–66). For the previous
irradiated patients the second course of EBRT ranged from
25 to 50 Gy (median 30 Gy), given in 1.8 to 2.0 Gy per
fraction. Using the linear quadratic model we have calcu-
lated the Biological Effective Dose (BED) given to the
tumor bed, assuming the α/β value of 10, for the EBRT, I-
HDR, second EBRT course and the total BED for all
courses of radiation, as shown in table 2.
For the 15 patients who had had a previous course of
EBRT, the total I-HDR median dose was 24 Gy, inferior to
the median dose of 40 Gy given to patients without a pre-
vious course of EBRT (p = 0.011), but with no influence in
OS (p = 0.9436) or LRFS (p = 0.6579), respectively. The
total value of BED above or inferior to 111 Gy10 also had
no impact on OS (p = 0.264) or LRFS (p = 0.7686). Table
3.
The crude local control rate was 52.4% (11/21 patients).
The 5- and 8-year overall (OS) and local relapse-free sur-
vival (LRFS) rates were 50%, 42.9%, 42.5% and 28.6%,
respectively, as shown in Figures 2 and 3. There was no
local failure within the irradiated area.
Table 2: Doses and Biological Effective Doses for all patients
Dose (Gy) BED (Gy10)
EBRT Second EBRT I-HDR Nominal Dose EBRT + I-HDR EBRT I-HDR Second EBRT Total
N2 11 5 2 1 2 1 2 1 2 1 2 12 1
Median 45.0 30.0 21.0 65.0 53.1 31.0 35.4 111.2
SD 14.0 9.3 10.3 11.6 13.8 17.9 10.9 22.2
Min. 30.0 25.0 7.0 46 53.1 13.0 29,5 62.2
Max. 66,0 50.0 42.0 105.0 86.1 91.0 59.0 146.8
Legend – n – number; SD – standard deviation; Min – minimum; Max – maximumRadiation Oncology 2006, 1:27 http://www.ro-journal.com/content/1/1/27
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Taking the data set of the 21 patients (Table 3), the only
statistical significant prognostic factor for LRFS and OS at
5 and 8 years was margin status, p = 0.0007 and p =
0.0002, respectively. Figure 4.
Doses at skin were measured and where in the range of
32–60%. Four patients (19.4%) experienced acute and
late adverse effects. Suture dehiscence occurred in 3
patients and one developed subcutaneous infection.
Severe late side effects as local ulcer and extensive neck
fibrosis were seem in 3 and 1 patient, respectively. There
was no soft tissue necrosis in the series.
Discussion
The presence of secondary neck node metastasis, as first
presentation or recurrence, is an adverse event that
impacts on survival. Salvage therapy in HNC is a contro-
versy issue, but the best combination approach seems to
be the maximum debulking surgery combined to irradia-
tion (primarily or a second course). Conventional EBRT as
a second course is generally limited by the tolerance of
surrounding normal tissues. Three-dimensional confor-
mal radiotherapy (3D-RT) or IMRT is time consuming,
cost effective treatments, and there is a lack of facilities in
developing countries [8].
The interstitial implantation is ideally suited to deliver a
high dose limited to the volume of the primary tumor site,
thus maximizing tumor control while minimizing com-
plications. With conventional EBRT alone, it is difficult to
spare adjacent normal tissues, resulting in undesirable late
effects on the salivary glands, mandible, and muscles of
mastication [9].
Regarding brachytherapy, a large experience has been
accumulated with interstitial low dose rate (I-LDR).
Grabenbauer et al published results of 318 patients
treated between 1985 and 1997 by I-LDR as part of their
primary (n = 236) or recurrent treatment (n = 82). A total
of 175 patients (55%) received a combination of surgery,
I-LDR (23–25 Gy) and EBRT (50–60 Gy), 60 patients
(19%) surgery and I-LDR (45–55 Gy) alone. At 5 years
they observed a better OS rate (p < 0.0001) for patients
receiving primary therapy. Median LRFS rates were 74%
and 57% at 5 years following primary and recurrent treat-
ment (p = 0.01), respectively. Late treatment-related toxic-
ity with soft tissue necrosis and/or osteonecrosis requiring
mandibular resection was 7.5% [10].
Lapeyre et al. in a recent publication reviewed the indica-
tions of postoperative I-LDR performed with Iridium 192
for SCC of the oral cavity with positive or close margins.
From 1979 to 1993, 82 patients were treated. Forty-six
patients had combined EBRT (mean dose of 48 Gy) and I-
LDR (mean dose of 24 Gy). Thirty-six patients had I-LDR
alone with a mean dose of 60 Gy. OS and LC at 5 years
were in the range of 22% to75% and 57% to 92%, respec-
tively, Predictive factors for OS and LC were positive lim-
phonodes (p = 0.009) and extra-capsular spread (p =
0.000001). The CS was only predictive for LC (p = 0.02)
[11].
Many institutions replaced the I-LDR I-HDR, with prelim-
inary results already published. I-LDR may improve the
LC after surgery because it can increase total dose admin-
istered, decrease the overall time, and is very conformal,
allowing protection of normal surrounding structures [6].
The literature is scarce regarding the use of I-HDR in treat-
ment of cervical region, and most reports are focused on
primary tumors of mobile tongue and oropharynx. A
phase I/II clinical trial tried to attempt for the use of I-
HDR as monotherapy for initial HN-SCC at the British
Columbia Cancer Agency, Vancouver Clinic, Canada, was
has been tested from 1989 to 1993. A total of 27 patients
Table 3: Local relapse-free rates
Variable n. patients Local control % P*
Age
≤ 65 years 15 7 56.7 0.3330
> 65 years 6 4 73.3
Primary site
Face 4 2 50.0 0.3485
Pharynx 10 5 50.0
Oral cavity 6 4 66.7
Unknown 1 0 0
Cumulative Dose
≤ 70 Gy 7 5 71.5 0.8920
> 70 Gy 14 6 52.8
I-HDR without EBRT
Yes 8 5 63.5 0.9436
No 13 6 53.8
I-HDR Total Dose
≤ 18 Gy 5 3 60.0 0.4365
> 18 Gy 16 8 50.0
Lymphnode mobility
Mobile 12 6 50.0 0.8814
Reduced 6 4 66.7
Fixed 3 1 33.3
Lymph fixation
Mobile 12 6 50.0 0.8966
Fixed 9 5 55.5
Margin status
Negative 13 11 84.6 0.0007
Positive 8 0 0
Previous radiation
Yes 15 8 53.3 0.6052
No 6 3 50.0
BED (Gy10)
≤ 111 10 4 40.0 0.7686
> 111 11 6 54.5
Total 21 11 52.3Radiation Oncology 2006, 1:27 http://www.ro-journal.com/content/1/1/27
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with T1-3 SCC from mobile tongue were treated with 7
fractions of 6.5 Gy, over a period of 3.5 days. The actuarial
LRFS was 53% at 5 years, lower than comparable histori-
cal controls [12]. Takacsi-Nagy et al. published data
regarding 21 patients with base of tongue tumors treated
with association of surgery and I-HDR between 1993 and
1999. Seventeen patients with advanced stage cancer
received I-HDR as a boost after 60–66 Gy EBRT and 4
patients with early stage (T1-2N0) were managed by
brachytherapy as sole treatment. The mean doses for com-
bined and sole I-HDR were 20 Gy (12–24 Gy) and 27 Gy
(24–30 Gy), respectively. At a mean follow-up time of 32
months the local tumor control for the entire patient pop-
ulation was 62%. (13/21). The incidence of grade 2 or
grade 3 mucositis were 48% and 52%, respectively [13].
We observed that 13 (61.9%) patients, in our analysis,
had had a previous course of irradiation, in which the
median total I-HDR dose was 25.8 Gy, inferior when com-
pared to the median dose of 40.7 Gy given to patients
without a previous course of EBRT (p = 0.011), but with
no influence in OS (p = 0.9436). Four patients (19.4%)
experienced acute and late adverse effects. Suture dehis-
cence was observed in 3 patients and one patient devel-
oped subcutaneous infection. Late side effects, graded as
severe complication, as extensive neck fibrosis and local
ulcer, happened in 1 and 3 patients, respectively, not
related to a higher dose to the skin or graft. There was no
soft tissue necrosis.
Leung et al. have published data regarding 19 patients
with early stage oral tongue cancer as treated by I-HDR.
The male-female ratio was 1:0.9, and the median age was
60 years, with a median dose given of 55 Gy in 10 frac-
tions over 6 days. They observed that the 4-year local fail-
ure-free survival rate was 94.7% and that one patient
treated with double planar implant had grade II necrosis
of the soft tissue [16].
In our analysis the only predictive factor for LFRS and OS
was the resection margin status, p = 0.0007 and p =
0.0002, respectively.
Some studies using pulsed-dose-rate (PDR) brachyther-
apy are also available. Strnad et al have already published
the results of interstitial PDR with regard to local control
and the incidence of side effects in patients with recur-
rences in a previously irradiated area. From 1997 to 2001,
43 patients received interstitial PDR brachytherapy. The
dose per pulse ranged from 0.4–0.7 Gy. Sixteen of 43
Kaplan Meier local relapse-free survival estimates by margin  status Figure 4
Kaplan Meier local relapse-free survival estimates by margin 
status.
Kaplan Meier overall survival estimates Figure 2
Kaplan Meier overall survival estimates.
Kaplan Meier local relapse-free survival estimates Figure 3
Kaplan Meier local relapse-free survival estimates.Radiation Oncology 2006, 1:27 http://www.ro-journal.com/content/1/1/27
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(37%) patients also received cisplatin or carboplatin with
5-fluorouracil during the time of treatment and 13/43
(30%) received EBRT in a dose range from 20–67 Gy. The
2-year LFRS and OS were 68% and 49%, respectively. For
patients treated with curative intention they were 80%
and 66%, respectively. They observed no statistical differ-
ence in the probability of local recurrence in patients sub-
grouped by recurrent tumor vs. secondary primary tumors
[15].
The Linear Quadratic Model is a toll that can make easy to
compare different fraction schedules. Assuming an α/β of
10, the most common value used for SCC, we found a
total BED in our analysis to be in the range of 66.2 to
148.6 Gy10. We observed that a higher BED was not a
prognostic factor for LRFS (p = 0.7686) or OS (p = 0.264).
Conversely, a publication by Levendag et al reporting the
use of I-HDR and PDR as primary treatment for 38
patients presenting with tonsillar fossa and/or soft palate
SCC treated between 1990 and 1994 using I-HDR or PDR.
The median cumulative dose of I-HDR or PDR with or
without additional EBRT was 66 Gy (range 55–73). They
observed that 5 (13%) patients developed local failure
with salvage surgery being possible in three of them and
that neither BT scheme nor tumor site significantly influ-
enced local control rates. Using the BED to compare
results with a group of 72 patients with similar tumor
characteristics and who underwent to EBRT alone they
observed that interstitial radiation, T stage, N stage, over-
all treatment time and BED were significant prognostic
factors for LRFS and OS at 3 years on univariate analysis.
Using Cox proportional hazard analysis, only T stage and
BED remained significant for LRFS (p < 0.001 and p =
0.008, respectively) [16].
The technological advances have made the use of I-HDR
more precise and appealing. For developing countries its
association with salvage surgery seems to be a reasonable
option, especially because of the high number of centers
that possesses the HDR after loading facilities, due the
high incidence of cervix cancer, and the lack of IMRT or
3D-RT.
In conclusion, our results suggest that I-HDR can be rec-
ommended in selected patients presenting local recur-
rences or second primary carcinomas after previous EBRT,
as it leads to a satisfactory local control rate with accepta-
ble morbidity. For patients who underwent to partial
resections dose should be increased to allow a better
tumor control. When IMRT is not suitable, the combina-
tion of I-HDR and salvage surgery, when feasible, seems to
the best salvage approach, but further studies are still
awaited.
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